Feasibility study of a high-performance data analytics pipeline for highly stratified approach to cardiovascular disease

针对心血管疾病的高度分层方法的高性能数据分析管道的可行性研究

• 批准号: 133852
• 金额: $ 6.67万
• 依托单位: PLAQUETEC LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133852
• 关键词: Feasibility; study; performance; data; analytics

"PlaqueTec has an advanced medical catheter that can detect biological signalling directly at the site of coronary artery disease. In clinical use it has shown that intracoronary biomarkers (i) differ depending on the state of disease ii) differ from patient to patient and iii) differ to systemic biomarker levels (i.e. those detected in standard blood sample). Leading clinicians recognise the potential for PlaqueTec's platform to enable personalised treatment strategies. PlaqueTec is now preparing to support investigator led studies (ILS) where clinicians and researchers (both industrial and academic) can access PlaqueTec's technology and data to help better diagnose and treat their patients.PlaqueTec's strategy, via a programme of investigator led studies, is to build world's most comprehensive database of coronary artery disease biomarkers. PlaqueTec will use machine learning and data science within a unique portal that will allow any patient's biomarker ""profile"" to be uploaded and assessed against the most meaningful patient cohorts to a) initially provide a more ""contextualised"" assessment of patient risk and b) ultimately predict therapeutic strategies most likely to offer benefit based on real world evidence.PlaqueTec's immediate challenge is to efficiently develop a scaleable, cloud based digital health system that can curate, analyse and output ""real world"" ILS data in a manner that delivers maximum utility to all potential stakeholders (clinicians, patients, regulators, therapy providers, governments and insurance companies).This feasibility project's objectives/questions:* **What functionality**: Engage with clinicians/stakeholders to define the key functionality of digital health system through which PlaqueTec will commercialise its services;* **What architecture**: Recommend and specify the analytics solution architecture that is best suited to meeting the stakeholder requirements;* **Best machine learning approach**: Identify the best data science and machine learning strategy given the composition of the PlaqueTec database.The enclosed project enables PlaqueTec to i) engage with potential end users and define requirements ii) work with Agile development and data science experts to develop a portal demonstrator and iii) test the ability of the portal demonstrator to answer stakeholder questions based on current datasets. The project will deliver a cloud-based architecture that can be rapidly scaled to provide commercial services to PlaqueTec's planned ILS programme.Innovation: today the treatment of coronary heart disease lacks precision. Massive progress has been made against cancer because patients are given highly specific/targeted treatments based on better biological profiling of their disease. This innovation aims to translate the same approach to coronary heart disease."

“PlaqueTec拥有一种先进的医疗导管，可以直接在冠状动脉疾病部位检测生物信号。在临床使用中，已经显示冠状动脉内生物标志物（i）根据疾病状态而不同，ii）在患者之间不同，和iii）与全身生物标志物水平（即在标准血液样品中检测到的那些）不同。领先的临床医生认识到PlaqueTec平台实现个性化治疗策略的潜力。PlaqueTec现在正准备支持研究者主导的研究（ILS），临床医生和研究人员（工业和学术）可以访问PlaqueTec的技术和数据，以帮助更好地诊断和治疗他们的患者。PlaqueTec的战略，通过研究者主导的研究计划，是建立世界上最全面的冠状动脉疾病生物标志物数据库。PlaqueTec将在一个独特的门户网站中使用机器学习和数据科学，该门户网站将允许上传任何患者的生物标志物“概况”，并根据最有意义的患者队列进行评估，以a）最初提供对患者风险的更“情境化”评估，以及B）最终预测最有可能提供基于真实的世界证据的治疗策略。PlaqueTec的直接挑战是有效地开发一种可扩展的基于云的数字健康系统，可以以向所有潜在利益相关者提供最大效用的方式管理、分析和输出“真实的世界”ILS数据（临床医生、患者、监管机构、治疗提供者、政府和保险公司）。本可行性项目的目标/问题：* 什么功能 **：与临床医生/利益相关者合作，定义PlaqueTec将通过其服务商业化的数字医疗系统的关键功能;* 什么架构 **：推荐并指定最适合满足利益相关者要求的分析解决方案架构;* 最佳机器学习方法 **：根据PlaqueTec数据库的组成确定最佳的数据科学和机器学习策略。所附项目使PlaqueTec能够i）与潜在的最终用户互动并定义需求ii）与敏捷开发和数据科学专家合作开发门户演示器，iii）测试门户演示器基于当前数据集回答利益相关者问题的能力。该项目将提供一个基于云的架构，可以快速扩展，为PlaqueTec计划中的ILS项目提供商业服务。创新：如今冠心病的治疗缺乏精确性。癌症治疗已经取得了巨大的进展，因为患者可以根据其疾病的更好生物学特征进行高度特异性/靶向治疗。这项创新旨在将相同的方法转化为冠心病。"